中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (5): 423-430.doi: 10.19401/j.cnki.1007-3639.2023.05.001
收稿日期:
2023-03-20
修回日期:
2023-05-08
出版日期:
2023-05-30
发布日期:
2023-06-16
通信作者:
王宇(ORCID: 003-2622-294X),博士研究生导师、主任医师,复旦大学附属肿瘤医院头颈外科主任。
作者简介:
渠宁(ORCID: 0000-0001-5670-4451),博士,副主任医师。基金资助:
QU Ning(), WANG Yuting, MA Ben, WANG Yu(
)
Received:
2023-03-20
Revised:
2023-05-08
Published:
2023-05-30
Online:
2023-06-16
Contact:
WANG Yu
文章分享
摘要:
甲状腺癌是近年来发病率显著升高的内分泌系统恶性肿瘤,治疗以外科治疗为主,术后根据情况辅以内分泌治疗、放射性核素治疗,某些情况下需辅以放疗、靶向治疗。然而甲状腺癌的死亡率亦有升高趋势,晚期或低分化/去分化患者的预后差且生存时间短。基础和临床研究的推进,使得甲状腺癌的个体化治疗取得了新进展。现对2022年度甲状腺癌领域的研究进展进行综述。
中图分类号:
渠宁, 王钰婷, 马奔, 王宇. 2022年度甲状腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2023, 33(5): 423-430.
QU Ning, WANG Yuting, MA Ben, WANG Yu. Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022[J]. China Oncology, 2023, 33(5): 423-430.
[1] |
ZHENG R, ZHANG S, ZENG H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Center, 2022, 2(1):1-9
doi: 10.1016/j.jncc.2022.02.002 |
[2] |
ZHOU M G, WANG H D, ZENG X Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158.
doi: S0140-6736(19)30427-1 pmid: 31248666 |
[3] | 张新洲, 刘劲松, 许娴, 等. 2005—2016年中国甲状腺癌发病和死亡趋势分析[J]. 中华肿瘤防治杂志, 2022, 29(24): 1725-1733. |
ZHANG X Z, LIU J S, XU X, et al. Trends of thyroid cancer incidence and mortality in China from 2005 to 2016[J]. Chin J Cancer Prev Treat, 2022, 29(24): 1725-1733. | |
[4] | CHEN W Q, ZHENG R S, ZUO T T, et al. National cancer incidence and mortality in China, 2012[J]. Chin J Cancer Res, 2016, 28(1): 1-11. |
[5] | HONGMEI, ZENG, PHD, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. |
[6] |
VACCARELLA S, LORTET-TIEULENT J, COLOMBET M, et al. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study[J]. Lancet Diabetes Endocrinol, 2021, 9(3): 144-152.
doi: 10.1016/S2213-8587(20)30401-0 |
[7] | 黄志刚, 陈晓红. 分化型甲状腺癌个体化分层治疗的策略和意义[J]. 中华耳鼻咽喉头颈外科杂志, 2017, 52 (6): 405-409 |
HUANG Z G, CHEN X H. The strategy and significance of individualized stratified therapy for differentiated thyroid carcinoma[J]. Chin J Otorhinolaryngol Head Neck Surg, 2017, 52(6): 405-409. | |
[8] |
ROMEI C, CIAMPI R, ELISEI R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma[J]. Nat Rev Endocrinol, 2016, 12(4): 192-202.
doi: 10.1038/nrendo.2016.11 pmid: 26868437 |
[9] | 贺青卿, 于芳, 范子义, 等. 单中心2 038例甲状腺癌20年随访及危险因素分析[J]. 中华内分泌外科杂志, 2022, 16(1): 18-22. |
HE Q Q, YU F, FAN Z Y, et al. Risk factor analysis of 20-year follow-up of 2 038 cases of thyroid cancer: a single center study[J]. Chin J Endocr Surg, 2022, 16(1): 18-22. | |
[10] |
LI X C, ZHANG S, ZHANG Q, et al. Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study[J]. Lancet Oncol, 2019, 20(2): 193-201.
doi: S1470-2045(18)30762-9 pmid: 30583848 |
[11] |
FRANCO A T, RICARTE-FILHO J C, ISAZA A, et al. Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers[J]. J Clin Oncol, 2022, 40(10): 1081-1090.
doi: 10.1200/JCO.21.01861 pmid: 35015563 |
[12] |
DOOLITTLE W K L, ZHAO L, CHENG S Y. Blocking CDK7-mediated NOTCH1-cMYC signaling attenuates cancer stem cell activity in anaplastic thyroid cancer[J]. Thyroid, 2022, 32(8): 937-948.
doi: 10.1089/thy.2022.0087 pmid: 35822558 |
[13] |
ZHANG P T, GUAN H X, YUAN S K, et al. Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors[J]. Nat Commun, 2022, 13(1): 1588.
doi: 10.1038/s41467-022-29000-5 |
[14] | 孙海燕, 弓磊, 于振涛, 等. 髓源性抑制细胞联合免疫检查点抑制剂抗肿瘤治疗的研究进展[J]. 肿瘤防治研究, 2020, 47(9)716-721 |
SUN H Y, GONG L, YU Z T, et al. Advances in anti-tumor therapy of myeloid-derived suppressor cells combined with immunological checkpoint inhibitors[J]. Cancer Res Prev Treat, 2020, 47(9)716-721 | |
[15] |
RABOLD K, ZOODSMA M, GRONDMAN I, et al. Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma[J]. Nat Commun, 2022, 13(1): 6149.
doi: 10.1038/s41467-022-33907-4 pmid: 36257966 |
[16] |
YIP L, SOSA J A. Molecular-directed treatment of differentiated thyroid cancer: advances in diagnosis and treatment[J]. JAMA Surg, 2016, 151(7): 663-670.
doi: 10.1001/jamasurg.2016.0825 pmid: 27223483 |
[17] | PENG S, LIU Y H, LV W M, et al. Deep learning-based artificial intelligence model to assist thyroid nodule diagnosis and management: a multicentre diagnostic study[J]. Lancet Digit Health, 2021, 3(4): e250-e259. |
[18] | MONTERO-CONDE C, LEANDRO-GARCÍA L J, et al.MARTÍNEZ-MONTES Á M, Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers[J]. Clin Transl Med, 2022, 12(8): e1001. |
[19] |
SUN Y T, SELVARAJAN S, ZANG Z L, et al. Artificial intelligence defines protein-based classification of thyroid nodules[J]. Cell Discov, 2022, 8(1): 85.
doi: 10.1038/s41421-022-00442-x pmid: 36068205 |
[20] |
SHI X, SUN Y, SHEN C, et al. Integrated proteogenomic characterization of medullary thyroid carcinoma[J]. Cell Discov, 2022, 8(1): 120.
doi: 10.1038/s41421-022-00479-y pmid: 36344509 |
[21] | National Cancer Center, Thyroid Cancer Expert Committee of National Cancer Quality Control Center. Quality control index for standardized diagnosis and treatment of thyroid cancer in China (2022 edition)[J]. Chin J Oncol, 2022, 44(9): 902-907. |
[22] |
FILETTI S, DURANTE C, HARTL D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(12): 1856-1883.
doi: S0923-7534(20)32555-2 pmid: 31987292 |
[23] |
ZHANG Z Y, SUN B T, OUYANG H, et al. Endoscopic lateral neck dissection: a new frontier in endoscopic thyroid surgery[J]. Front Endocrinol (Lausanne), 2021, 12: 796984.
doi: 10.3389/fendo.2021.796984 |
[24] | 中国抗癌协会. 中国肿瘤整合诊治指南(CACA)甲状腺癌2022版[M]. 天津科学技术出版社, 2022. |
China Anti-Cancer Association. China Cancer Integrated Diagnosis and Treatment Guidelines (CACA) for thyroid cancer 2022 edition[M]. Tianjin Science and Technology Press, 2022. | |
[25] | 中华人民共和国国家卫生健康委员会医政医管局. 甲状腺癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022, 42(12): 1343-1357, 1363. |
National Health Commission of the People’s Republic of China Medical Administration and Hospital Administration. Guidelines for the diagnosis and treatment of thyroid carcinoma[J]. Chin J Pract Surg, 2022, 42(12): 1343-1357, 1363. | |
[26] | 纪玲霞, 周爱琴, 周雪梅. 调强放疗治疗甲状腺癌术后残留和复发的临床效果研究[J]. 实用癌症杂志, 2022, 37(5): 858-860 |
JI L X, ZHOU A Q, ZHOU X M. Clinical study on the effect of intensive modulation radiotherapy in the treatment of residue and recurrence after thyroid cancer[J]. Pract J Cancer, 2022, 37(5): 858-860 | |
[27] |
KWON J, KIM B H, JUNG H W, et al. The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a systematic review and meta-analysis[J]. Eur J Cancer, 2016, 59: 34-45.
doi: S0959-8049(16)00130-1 pmid: 27014798 |
[28] |
ORLANDI F, CARACI P, BERRUTI A, et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer[J]. Ann Oncol, 1994, 5(8): 763-765.
pmid: 7826911 |
[29] |
SCHLUMBERGER M, LEBOULLEUX S. Current practice in patients with differentiated thyroid cancer[J]. Nat Rev Endocrinol, 2021, 17(3): 176-188.
doi: 10.1038/s41574-020-00448-z pmid: 33339988 |
[30] |
HO A L, DEDECJUS M, WIRTH L J, et al. Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase Ⅲ, randomized, placebo-controlled trial (ASTRA)[J]. J Clin Oncol, 2022, 40(17): 1870-1878.
doi: 10.1200/JCO.21.00714 |
[31] |
CAO J J, ZHU X L, SUN Y R, et al. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(10): 3470-3481.
doi: 10.1007/s00259-022-05820-x |
[32] |
NABHAN F, DEDHIA P H, RINGEL M D. Thyroid cancer, recent advances in diagnosis and therapy[J]. Int J Cancer, 2021, 149(5): 984-992.
doi: 10.1002/ijc.33690 pmid: 34013533 |
[33] | National Comprehensive Cancer Network. NCCN clinical practice guidelines in thyroid cancer (2022 version Ⅰ)[DB/OL]. [2023-04-28]. http://www.nccn.org. |
[34] |
SUBBIAH V, KREITMAN R J, WAINBERG Z A, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase Ⅱ ROAR basket study[J]. Ann Oncol, 2022, 33(4): 406-415.
doi: 10.1016/j.annonc.2021.12.014 |
[35] |
HUANG N S, WEI W J, XIANG J, et al. The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase Ⅱ clinical trial[J]. Thyroid, 2021, 31(12): 1808-1813.
doi: 10.1089/thy.2021.0307 |
[36] |
SARONNI D, GAUDENZI G, DICITORE A, et al. Preclinical evaluation of novel tyrosine-kinase inhibitors in medullary thyroid cancer[J]. Cancers (Basel), 2022, 14(18): 4442.
doi: 10.3390/cancers14184442 |
[37] | 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021, 34(12): 1164-1201. |
Working Committee of the Guidelines of the Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology (CSCO) differentiated thyroid cancer[J]. J Cancer Control Treat, 2021, 34(12): 1164-1201. | |
[38] |
SUBBIAH V, HU M I, WIRTH L J, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study[J]. Lancet Diabetes Endocrinol, 2021, 9(8): 491-501.
doi: 10.1016/S2213-8587(21)00120-0 |
[39] | RAMAN R, VILLEFRANC J A, ULLMANN T M, et al. Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer[J]. J Exp Med, 2022, 219(6): e20210390. |
[40] | LEE Y A, LEE H, IM S W, et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake[J]. J Clin Invest, 2021, 131(18): e144847. |
WAGUESPACK S G, DRILON A, LIN J J, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma[J]. Eur J Endocrinol, 2022, 186(6): 631-643.
doi: 10.1530/EJE-21-1259 |
[1] | 刘帅, 张凯, 张晓青, 栾巍. 派安普利单抗联合安罗替尼和化疗围手术期治疗局部进展期胃癌的探索性研究[J]. 中国癌症杂志, 2024, 34(7): 659-668. |
[2] | 郝弦, 黄建军, 杨文秀, 刘晋廷, 张军红, 罗钰蓓, 李青, 王大红, 高玉炜, 谭福云, 薄莉, 郑羽, 王荣, 冯江龙, 李静, 赵春华, 豆晓伟. 乳腺癌原代细胞系为药物筛选和基础研究提供癌症新模型[J]. 中国癌症杂志, 2024, 34(6): 561-570. |
[3] | 上海市抗癌协会胃癌专业委员会, 中国人体健康科技促进会胃肠肿瘤专业委员会. 侵犯邻近脏器的进展期胃癌的临床诊疗中国专家共识(2024年版)[J]. 中国癌症杂志, 2024, 34(5): 517-526. |
[4] | 钱斌, 陈海泉. 2023年度肺癌外科治疗领域重要进展[J]. 中国癌症杂志, 2024, 34(4): 335-339. |
[5] | 冯征, 郭勤浩, 朱俊, 吴小华, 温灏. 2023年度妇科恶性肿瘤治疗进展及展望[J]. 中国癌症杂志, 2024, 34(4): 340-360. |
[6] | 许永虎, 徐大志. 21世纪以来胃癌治疗进展及未来展望[J]. 中国癌症杂志, 2024, 34(3): 239-249. |
[7] | 汪学非, 周鹏, 唐兆庆. 胃癌外科治疗的新进展及发展趋势[J]. 中国癌症杂志, 2024, 34(3): 250-258. |
[8] | 张琪, 修秉虬, 吴炅. 2023年中国乳腺癌重要临床研究成果及最新进展[J]. 中国癌症杂志, 2024, 34(2): 135-142. |
[9] | 张思源, 江泽飞. 2023年改变晚期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 143-150. |
[10] | 王昭卜, 黎星, 于鑫淼, 金锋. 2023年改变早期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 151-160. |
[11] | 刘志昱, 徐栋, 陈西昊, 李纪鹏. 局部进展期直肠癌新辅助放化疗后肿瘤退缩的影响因素分析及预测模型构建[J]. 中国癌症杂志, 2024, 34(2): 191-200. |
[12] | 李天骄, 叶龙云, 金凯舟, 吴伟顶, 虞先濬. 2023年度胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2024, 34(1): 1-12. |
[13] | 李桐, 杨慧娟. 卵巢黏液性癌的诊治进展[J]. 中国癌症杂志, 2024, 34(1): 90-96. |
[14] | 薛丽琼, 郭晔, 陈立波. 晚期甲状腺癌靶向药物不良反应管理专家共识(2023年版)[J]. 中国癌症杂志, 2023, 33(9): 879-888. |
[15] | 康殷楠, 陈顺, 解有成, 郑英, 何昱静, 李初谊, 于晓辉. 抗体药物偶联物在HER2阳性晚期胃癌中的应用进展和展望[J]. 中国癌症杂志, 2023, 33(8): 790-800. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||
地址:上海市徐汇区东安路270号复旦大学附属肿瘤医院10号楼415室
邮编:200032 电话:021-64188274 E-mail:zgazzz@china-oncology.com
访问总数:; 今日访问总数:; 当前在线人数:
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn